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Abstract Nanoparticles (NPs) fabricated from the bio-
degradable copolymer poly(lactic-co-glycolic acid)
(PLGA) were investigated as a drug delivery system to
enhance the photodynamic efficacy of 5-aminolevulinic
acid (5-ALA) in mice bearing Ehrlich ascites carcinoma.
The PLGA-encapsulated 5-ALA NPs were prepared using
binary organic solvent diffusion method and characterized
in terms of shape and particle size. The in vivo photody-
namic efficiency in Ehrlich ascites-bearing mice was
studied. The obtained particles were uniform in size with
spherical shape of mean size of 249.5 nm as obtained by
particle size analyzer and the in vitro release studies
demonstrated a controlled release profile of 5-ALA.
Tumor-bearing mice injected with PLGA-encapsulated
5-ALA NPs exhibited significantly smaller mean tumor
volume, increased tumor growth delay compared with the
control group and the group injected with free 5-ALA
during the time course of the experiment. Histopathological
examination of tumor from mice treated with PLGA-
encapsulated 5-ALA NPs showed regression of tumor cells,
in contrast to those obtained from mice treated with free
5-ALA. The results indicate that PLGA-encapsulated
5-ALA NPs are a successful delivery system for improving
photodynamic activity in the target tissue.
Keywords Photodynamic therapy (PDT)  Nanoparticles
(NPs)  Photosensitizer (PS)  5-Aminolevulinic acid
(5-ALA)  Poly-lactide-co-glycolide (PLGA)  Percentage
of drug entrapment (PDE)  Drug loading  Drug release
Introduction
Photodynamic therapy also known as PDT, photo-radiation
therapy, phototherapy, or photo chemotherapy is a prom-
ising treatment for a variety of oncological, cardiovascular,
dermatological and ophthalmic diseases. PDT is emerging
as an alternative modality for cancer therapy for the
treatment of light accessible tumors (Saxena 2005).
Photodynamic therapy incorporates a photosensitizer
(PS), light source, and oxygen. Individually, the compo-
nents are nontoxic. The activated (irradiated) form of the
photosensitizer is toxic at the site of action (Issa and
Manela-Azulay 2010; Yoo et al. 2012). Among various
photosensitizers, 5-aminolevulinic acid (5-ALA) is a pre-
cursor of a strong photosensitizing agent, protoporphyrin
IX (PpIX) and has been used extensively in clinical
applications, due to its safety, feasibility as an effective
endogenous photosensitizer for fluorescence diagnosis, and
its efficacy in PDT. However, owing to the poor penetra-
tion of ALA into skin, ALA–PDT is inappropriate for
difficult-to-treat deep skin neoplasias (Donnelly et al.
2010). As most photosensitizers, 5-ALA is characterized
by a high lipophilicity. Although interesting with respect to
the selectivity for neoplastic tissue, the resulting insolu-
bility in physiologically acceptable media makes the sys-
temic administration of conventional PS problematic and
restricts their medical applications (Castano et al. 2005;
Konan et al. 2002). To overcome this limitation, PS have
been associated with colloidal carriers such as liposomes,
emulsions, microparticles or nanoparticles as reviewed by
Konan et al. (2002). The interest in nanocarriers such as
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polymeric nanoparticles (NPs) to enable the production of
an injectable suspension of PS has been increasing over
recent years. NPs made of a polymeric matrix are a very
stable and biocompatible drug delivery system.
Polymeric NPs have the potential to dramatically
improve the diagnosis and treatment of tumor (Lee et al.
2012; Qian et al. 2008). The ability to fine-tune the prop-
erties of nanoparticles by controlling their components in
the core or the shell region renders them useful and optimal
for pharmaceutical purposes (Lee et al. 2012; Ferrari
2005). Among them, Poly(D,L-lactide-co-glycolide)
(PLGA) NPs have been demonstrated as excellent carriers
for imaging and targeting of tumor cells and for carrying
anti-tumor drugs to tumor cells, due to their unique features
including biocompatibility, biodegradability, tailor-made
functionality, and the large interior cargo volume (Lee
et al. 2004, 2012; Zhang et al. 2007).
5-Aminolevulinic acid was simply conjugated to PLGA
NPs for enhancing the nanoparticles stability in the PDT.
The conjugation of 5-ALA to PLGA NPs was designed to
perform photodynamic tumor therapy by generating reac-
tive oxygen species (e.g., singlet oxygen: 1O2) from light
absorption. The released reactive oxygen species lead to
irreversible damage to the treated tumor cells (Oh et al.
2012; Park et al. 2011).
In this study, we prepared PLGA NPs by emulsion
solvent evaporation method compared with the binary
organic solvent diffusion (BOSD) method, and studied
the possibility of nanoparticles as drug carriers by using
5-ALA as a model of photosensitizer drug. The drug
loading contents, loading efficiency, changes of particle
size, and physicochemical properties of PLGA NPs
after the drug is entrapped into the nanoparticles are
investigated. Also the use of laser and PLGA-encapsu-
lated 5-ALA NPs as possible dual-mode enhancement




Poly (D,L-lactide-co-glycolide) (PLGA, lactide/glycolide
molar ratio = 85/15, average Mw 50,000–75,000), 5-am-
inolevulinic acid hydrochloride, poly (vinyl alcohol),
87–89 % hydrolyzed, average Mw 13,000–23,000 all those
was provided by Sigma Chemical Co. USA, and all other
chemicals and solvents were of reagent grade.
PLGA nanoparticles preparation
PLGA NPs were prepared as follows.
Spontaneous emulsification solvent diffusion (SESD)
Briefly, 60 mg of PLGA (85:15) were first dissolved in
25 mL of acetone; this organic phase was poured at the rate
of 0.4 mL/min into 30 mL phosphate buffer (pH 7.4,
5 mM) containing 100 mg PVA as the hydrophilic sur-
factant under moderate magnetic stirring of 2,000 rpm.
Finally, the organic solvents were evaporated under reduced
pressure at 58 C, and the final volume of the aqueous sus-
pension was adjusted to 10 mL (Lamprecht 1999).
But this method resulted in nanoparticles of large mean
size of about 233 nm.
Binary organic solvent diffusion (BOSD) (Jiang et al.
2003)
1. 60 mg of PLGA (85:15) was first dissolved in 17 mL
of acetone in a glass beaker then 8 mL of ethanol is
added drop-wise using a 22-gauge micro-infusion
syringe pump at rate of 0.4 mL/min into 30 mL double
distilled water containing 100 mg PVA as the hydro-
philic surfactant with stirring of 2,000 rpm with the
help of a high-speed magnetic stirrer.
2. After addition of the organic solvent, the solution
stirred on the high-speed magnetic stirrer for about one
extra day.
Purification
3. The organic solvents of acetone and ethanol were
evaporated under reduced pressure at 58 C using rotary
evaporator and then centrifuged at 12,000 rpm for 1 h.
4. The precipitate was washed with 25 mL distilled
water. This centrifugation and washing process was
repeated three times to remove the PVA and residual
organic solvents.
Freeze-drying
5. The precipitate was frozen by vacuum freeze-drying
machine (Lyophilizer) (Model/CRYODOS-50, Spain)
at 230 V, 50 Hz, at a pressure of 26.5 Pa and 5 %
saccharose was used as cytoprotectant. The lyophilized
particles were then characterized.
Characterization of PLGA nanoparticles
Particle size (Thakkar et al. 2004)
The particle size distribution of the nanoparticles was
determined by laser light scattering on a Beckman Coulter
Particle Size Analyzer (N5 submicron particle size
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analyzer, Japan) equipped with a He–Ne Laser beam at a
fixed scattering angle of 11.1. The nanoparticles suspen-
sion were added to the sample dispersion unit containing
the stirrer and stirred to reduce the aggregation between the
particles, and laser obscuration range was maintained at
15–20 %. The mean particle size was measured after per-
forming the experiment in triplicate.
Shape of PLGA nanoparticles (Gupta and Jabrail 2006)
The physical size and shape of the prepared nanoparticles
were determined by transmission electron microscope
(JEOL-JSM-6360LA, Japan). For this purpose, the particle
suspension was diluted 10 times with distilled water and
deposited drop-wise onto a 400-mesh copper grid coated
with carbon film, and were allowed to dry in the air before
studying by microscope.
Fourier-transform infrared spectroscopy (FTIR) (Bhumkar
and Pokharkar 2006)
Fourier-transform infrared (FTIR) spectra of the blank
PLGA NPs were obtained on a Shimadzu FTIR-8400S
(Tokyo, Japan). The pellets were prepared by grinding
4–8 mg of samples with 200 mg potassium bromide and by
a compression using Shimadzu compressor (Japan) tablets
were prepared then fixed on holder to be examined. The
spectra were scanned over the wave number range of
4,600–500 cm-1 in which the region of 4,600–600 cm-1
are called the functional group region.
Thermo-gravimetric analysis (TGA) (Bhumkar
and Pokharkar 2006)
The compositions of the prepared nanoparticles were
determined by thermo-gravimetric analysis (TGA) (TGA
50, Shimadzu, Japan). The weight of the dried nanoparti-
cles for the TGA experiment was between 13 and 16 mg.
The experiments were conducted using closed aluminum
pans with a cover hole. The sample was examined under a
nitrogen flow rate of 20 mL/min at a scan rate 10 C/min
with the range from 25 to 600 C.
Determination of encapsulation efficiency (Thakkar et al.
2004)
The percentage of drug entrapment (PDE) was calculated
according to Eq. (1) as following:
PDE %ð Þ ¼ Actual drug content
Theoretical drug content
 100% ð1Þ
Theoretical drug content was determined assuming that
the entire drug present in the PLGA solution used gets
entrapped in nanoparticles and no loss occurs.
The actual drug content in the 5-ALA loaded PLGA
nanoparticles was quantitatively determined by the fol-
lowing procedure:
First standard curve from known concentration of
5-ALA was constructed. Freeze-dried nanoparticles were
weighted and suspended into methanol and vigorously
stirred for 3 h and sonicated for 15 min. Resulting solution
was centrifuged at 12,000 rpm for 20 min. The supernatant
was taken for measurement of drug concentration using
ultraviolet (UV)/visible spectrophotometer (new Jenway
Model 6315) at 670 nm. The drug loading efficiency
(DLE) was presented by Eq. (2) (Nah et al. 2000).
DLE ¼ Weight of drug in nanoparticles
Weight of nanoparticles
ð2Þ
In vitro drug release
The in vitro drug release study was performed in triplicate.
Briefly, 15 mg freeze-dried drug-loaded nanoparticles was
suspended in 50 mL phosphate buffer saline (PBS), pH 7.4,
in a glass flask and sonicated using Bransonic Ultrasonic
B-220 for 10 min to get a homogenous suspension. This
suspension was kept in shaking on a mechanical shaking
bath shaken horizontally at 100 cycles/min, with temper-
ature adjusted to 37 C. At different time intervals, a
sample volume of 1.5 mL was transferred and centrifuged
at 10,000 rpm for 15 min. A quantity of 1 mL of the
supernatant was taken for laser analysis at 670 nm. 1 mL
of fresh PBS buffer was added to the remaining 0.5 mL
sample. 1.5 mL of the suspension was agitated vigorously
by vortexing and replaced in the flasks. The cumulative
percentage of 5-ALA released from the nanoparticles at a
certain time point was obtained using Eq. (3).
Cumulative 5  ALA released %
¼ 100  5  ALA remainingð Þ% ð3Þ
The same procedure was repeated where the sample
were irradiated to a diode laser at 650 nm laser beam from
a He–Ne laser (photon company) as measured by
spectrometer, the power of each laser on the sample was
150 mW. During the experiments, the laser beam was
delivered to the tubes containing samples with an
irradiation spot of 7 mm diameter. The fluency rate was
3.90 mW/mm3. Laser irradiation lasted for 11 min, and
then a sample volume of 1.5 mL was transferred and
centrifuged at 10,000 rpm for 15 min. A quantity of 1 mL
of the supernatant was taken for laser analysis at 670 nm.
1 mL of fresh PBS buffer was added to the remaining
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0.5 mL sample. 1.5 mL of the suspension was agitated
vigorously by vortexing and replaced in the flasks.
Animal care
In vivo studies were done on a total of 80 male Swiss
albino mice 6–8 weeks old, weighing 16–25 g, purchased
from animal house at National Cancer Institute, Cairo
University. Ten animals each were housed in plastic cages
in a well-ventilated room (25 ± 2 C) with a relative
humidity of (43 ± 3 %) and maintained on a high protein
basal diet.
PDT protocol
Animals were acclimated to the environment for at least
2 weeks before onset of the experiment. Ehrlich ascites
carcinoma cells, 2 9 106 mammary in origin, diluted
approximately (1–4) in 0.2 mL normal saline. The mouse’s
leg was shaved; the thigh skin was pulled up with forceps,
and then inoculated subcutaneously.
The treatment protocol started with intralesional injec-
tion on the eighth day after tumor implantation. Animals
were anesthetized with ketamine/xylazine/acepromazine
and the dose of PLGA NPs administrated to each mouse
was equivalent to 20 mg/kg which were suspended in
saline and sonicated for 10 min before injection to get a
homogenous suspension then directly injected into the
tumor interstitial coordinates using insulin syringe. Within
2 min of injection to limit particle diffusion beyond the
tumor boundaries, animal tumors were extra-corporeally
exposed for 11 min to 670 nm visible diode laser at power
of 150 mW (Casas et al. 1999) for each other day for
1 week (three times/week). During the experiment, laser
beam was delivered to the tumor with an irradiation spot
directly on the skin over the tumor of 7 mm diameter;
fluency rate was 3.90 mW/mm2 at room temperature
(25 ± 2 C). During the procedure, a homemade
thermo sensitive sensor connected to computer is to mon-
itor the thermal transient of tumor and measure its tem-
perature using a across a software interface the circuit of
the sensor.
Experimental design
The animals injected with tumor cells were subdivided into
four main groups each comprising 20 animals as follows:
Group I mice injected with free 5-ALA at dose of
20 mg/kg.
Group II mice injected with PLGA-encapsulated 5-ALA
NPs at dose equivalent of 20 mg/kg.
Group III mice injected with blank PLGA NPs.
Group IV mice injected with 50 lL normal saline and
serve as the control untreated group.
Each group was divided into two subgroups each of 10
mice; subgroup A which did not receive laser irradiation.
While subgroup B irradiated with laser beam for 11 min
each other day (three times/week) for 1 week.
Inhibitory effect of 5-ALA loaded on nanospheres
To study the cytotoxic effect of 5-ALA loaded on PLGA
nanospheres irradiated with laser on the tumor in different
animal groups, the following parameters were estimated as
follows.
Tumor volume
The tumor was measured every other day between the skin
surface layers. Tumor volume was estimated using Eq. (4)
as follows (Tang et al. 2007).
Volume of tumor ¼ Dmax  Dminð Þ2=2: ð4Þ
where Dmax maximum diameter, Dmin minimum diameter
Tumor volume ratio (TVR) (Chen et al. 2004)
TVR ¼ Tumor volume after treatment
tumor volume before treatment
ð5Þ
Inhibition ratio of tumor (Tang et al. 2007)
Inhibition ratio of tumor ¼ 1  f (average tumor volume
at beginning  average tumor
volume at the end of treatment)=ðaverage tumor volume
of control at beginning  average
tumor volume of control at the end of treatment)g
ð6Þ
Tumor growth relative rate (TGRR) (Venslauskas
and Batiuskaite 2003)
The tumor growth at a given moment is dependent on the
size of tumor cell population at the previous time interval
and that the tumor growth rate at different time interval is
not steady. On the other hand, under the influence of
anticancer drug tumor growth could be stopped or
reduced. These findings suggest proposing a new quanti-
tative measure-tumor growth relative rate (TGRR) defined
as:




where vt is tumor volume at the present time interval, v(t-1)
is the tumor volume at the previous time interval, Dt is
the time interval between the measurements so rt is the
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value of the tumor volume change per day expressed by
part of the former volume.
Biochemical analysis
Blood samples were collected when the mice were killed.
Sera were harvested by centrifugation at 3,500 rpm and
stored in aliquots at -80 C until assayed. Serum TNF-a
were determined using enzyme linked immunosorbent
assay (ELISA) kit for the quantitative detection of TNF-a
(eBioscience, Europe) according the producer’s protocol.
Histopathological study
Light microscopic examination On dissection, tumor sam-
ples were excised from animals of each group and pre-
served in a 10 % formalin solution for histopathological
sections. The fixed tissues were embedded in paraffin;
sections 3–5 lm thick were obtained, deparaffinized,
dehydrated in ethanol (50–100 %), and cleared with
xylene. The extent of induced cytotoxicity, including
inflammation, cell apoptosis, cell necrosis, steatosis and
others was evaluated by assessing the morphological
changes in tumor sections stained with hematoxylin and
eosin (H&E) under light microscope.(Bancroft et al. 1996)
Results and discussion
Characterization of blank PLGA and PLGA-
encapsulated 5-ALA NPs
Particle size
Figure 1a shows the particle size distribution curve, as
measured by particle size analyzer, for blank PLGA NPs
prepared by SESD method, sharp distribution range of
nanoparticles, with 90 % of spheres in size range of
130–290 nm with mean size of 233.1 nm and only 10 %
were oversized at diffraction angle of 11.1 with baseline
error of 0.01 % and poly-dispersity index of 0.856 (\1)
which indicates homogeneous distribution of the particles.
These results were in accordance with Murakami et al’s.
(1999) study regarding production of PLGA NPs suggested
that the original SESD method sometimes causes a severe
aggregation in the particle formation process, resulting in
formation of nanoparticles with larger size. This indicates
that the SESD method should be modified. While Fig. 1b
shows the particle size distribution curve for blank PLGA
NPs prepared by BOSD method, sharp distribution range of
nanoparticles, with 90 % of spheres in size range of
100–140 nm with mean size of 124.6 nm and only 10 %
were oversized at diffraction angle of 11.1 with baseline
error of 0.01 % and poly-dispersity index of 0.784 which
also indicates homogeneous distribution of the particles.
The binary organic solvents used were acetone and ethanol
at the volume fraction of (2/1). The sizes of PLGA (85:15)
NPs changes from 233 to 124 nm. Since ethanol has larger
affinity to water than acetone and accelerates the diffusion
of PLGA during dispersion process. This benefits the fast
formation of NPs and avoids the aggregation of small
particles, which results in the production of NPs with larger
size (Wu et al. 2011).
Figure 1c shows the particle size distribution curve for
PLGA-encapsulated 5-ALA NPs, it shows distribution range of
nanoparticles, with 90 % of spheres in size range of
160–360 nm with mean size of 249.5 nm and only 10 % were
oversized at diffraction angle of 11.1 with baseline error of
0.02 % and poly-dispersity index of 18.480 (more than 1) which
indicates inhomogeneous distribution of the particles. Here, the
increase in size is due to the addition of 5-ALA in NPs.
Transmission electron microscope (TEM)
Figure 2a shows TEM examination for PLGA NPs pre-
pared by SESD method; it revealed the presence of com-
pletely spherical PLGA NPs with smooth surfaces, and no
agglomeration formed.
While Fig. 2b shows TEM examination for blank PLGA
NPs prepared by BOSD method, it revealed the presence of
Fig. 1 The particle size distribution curve for a free PLGA NPs prepared by SESD method. b Free PLGA NPs prepared by BOSD method.
c PLGA-encapsulated 5-ALA NPs prepared by BOSD method
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completely spherical PLGA NPs with low level of
agglomeration or adhesion that occurred among particles
and high level of uniformity. But for PLGA-encapsulated
5-ALA NPs, Fig. 2c showed increased in size compared to
free PLGA NPs and no change in the spherical shape which
mean that the spherical shape of blank PLGA NPs has not
been compromised.
Fourier-transform infrared spectroscopy (FTIR)
For the IR spectrum of PLGA polymer, the characteristic
absorption bands appeared at wave number 3,023 and
2,401 cm-1 (CH bend), 1,759 cm-1 (C=O ester), 1,520,
1,451, 1,378 cm-1 (CH3), 1,215, 1,126, 1,093 cm
-1 (C–O
stretch), 748, 671 cm-1 (CH– bend) while the band at
4,214 and 3,685 cm-1 belongs to the OH group of the
water molecule. While for blank PLGA NPs stabilized by
PVA, it shows the characteristic absorption bands at wave
number 3,423 cm-1 (OH group), 2,954 cm-1 (CH alkyl
group), 2,866, 2,075 cm-1 (CH bend), 1,730 cm-1 (C=O
ester), 1,631, 1,456, 1,379 cm-1 (CH3), 1,276, 1,195,
1,126 cm-1 (C–O stretch), 1,080 cm-1 (CH2), 945,
732 cm-1 (CH– bend). Also for PLGA-encapsulated
5-ALA NPs, it shows the same characteristic absorption
bands at 3,438, 2,960, 2,867, 2,071, 1,724, 1,635, 1,458,
1,379, 1,274, 1,197, 1,126, 1,078, 642, 520 cm-1, in
addition to a new band at 1,033 cm-1 that C–O bond.
Comparing the obtained IR spectra for PLGA polymer,
blank PLGA NPs and PLGA-encapsulated 5-ALA NPs as
in Fig. 3 with the IR spectra characteristic for PLGA, PVA
and 5-ALA shown in the literature, it confirmed that the
obtained NPs are composed of PLGA and PVA with no
interaction with 5-ALA. It was confirmed that there are no
major shifting as well as no loss of functional peaks
between the spectra of drug, polymer and drug-loaded NPs
(3,438, 2,960, 2,867, 2,071, 1,724, 1,635, 1,458, 1,379,
1,274, 1,197, 1,126, 1,078, 642, 520 cm-1). Besides the
characteristic groups for PLGA, the large bands observed
between 3,550 and 3,200 cm-1 are linked to the stretching
O–H from the intermolecular and intramolecular hydrogen
bonds. The vibrational band observed between 2,840 and
3,000 cm-1 refers to the stretching C–H from alkyl groups
and the peaks between 1,750 and 1,735 cm-1 are due to the
stretching C–O and C–O from acetate group remaining
from PVA (Mansur et al. 2008; Andrade et al. 2008).
Our results coincide with the results obtained by dos
Reis et al. Their results indicated that FTIR spectrum of
pure PVA sample clearly reveals the major peaks associ-
ated with poly(vinyl alcohol) that can be observed C–H
broad alkyl stretching band (m = 2,850–3,000 cm-1) and
typical strong hydroxyl bands for free alcohol (nonbonded–
OH stretching band at m = 3,600–3,650 cm-1), and
hydrogen bonded band (m = 3,200–3,570 cm-1) (Budhian
et al. 2007; Jain 2000). Intramolecular and intermolecular
Fig. 2 TEM of a blank PLGA NPs prepared by SESD. b Blank PLGA NPs prepared by (BOSD). c TEM of PLGA-encapsulated 5-ALA NPs. All
in 940
Fig. 3 Fourier-transform
infrared spectra of PLGA
polymer, blank PLGA NPs and
PLGA-encapsulated 5-ALA
NPs
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hydrogen bonding are expected to occur among PVA
chains due to high hydrophilic forces. An important
absorption peak was verified at m = 1,142 cm-1. This band
has been used as an assessment tool of PVA structure
because it is a semi-crystalline synthetic polymer able to
form some domains depending on several process param-
eters (John Coates and Meyers 2000; Elizabeth Fonseca
dos Reis et al. 2006).
Our results are in agreement with the results obtained by
Jawahar et al. They designed PLGA NPs for ramipril as
anti-hypertensive agent confirmed no loss of functional
groups of PLGA when processed into NPs loaded with
ramipril (1,652, 1,701, 1,743, 2,866, 1,323 cm-1) (Jawahar
et al. 2009).
Thermo-gravimetric analysis (TGA)
Figure 4a shows TGA for PLGA powder which shows only
one strong peak at 232–402 C with 96.66 % loss of
weight.
While Fig. 4b shows TGA for free PLGA NPs which
shows three peaks, the larger one at 175–383 C with
81.599 % loss of weight, next by shorter peak at
383–479 C with 7.85 % loss of weight and the shortest
peak at 479–566 C with 5.783 % loss of weight.
While Fig. 4c shows TGA for PLGA-encapsulated
5-ALA NPs which shows four intermediate peaks at
24–135 C with 37.654 % loss of weight, next by a very
short peak at 135–159 C with 7.962 % loss of weight and
return to a stronger peak at 176–299 C with 33.081 % loss
of weight and ended by an intermediate peak at
324–402.5 C with 17.832 % loss of weight.
Characterization of drug loading
According to Eqs. 1 and 2, PDE was 66.8 %, while DLE
was 12.74 %. The drug load was 127.5 lg drug/mg
nanoparticles for PLGA NPs containing 5-ALA as shown
in Table 1.
These results confirm the result of Jawahar et al. They
prepared PLGA NPs containing ramipril a hypertensive
agent with high PDE of 68.28 % (2009), while Budhian
et al. (2008) prepared PLGA NPs (200 nm) encapsulating
hydrophilic drug haloperidol with drug content of 0.2 %.
Fig. 4 TGA of a PLGA powders. b Blank PLGA NPs. c PLGA-encapsulated 5-ALA NPs
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The high 5-ALA incorporation efficiency in PLGA can
be attributed to several factors:
Firstly, the hydrophobic nature of PLGA molecules
makes it relatively easy to entrap hydrophobic 5-ALA into
PLGA NPs.
Secondly, the hydrophobic nature of 5-ALA results in a
minimum loss of the drug to the external aqueous phase
during the interfacial deposition preparation process.
The high entrapment efficiency proves that the affinity
between 5-ALA and PLGA matrix was far stronger than
the affinity between 5-ALA and external aqueous phase.
Thirdly, the drug incorporation method and variables
such as, incubation time, temperature, stirring, solvent,
presence of surfactants, MW of PLGA, L:G ratio of
PLGA, PLGA concentration, removal rate of organic
solvent, etc., are also factors which may influence drug
entrapment efficiency (Kader et al. 1998) and this in
accordance with the explanation of Zeng and Sun
(2009).
Figure 5a showed initial burst release profile of 54 %
of 5-ALA from PLGA NPs after 24 h followed by a
slower release rate that lasts for 12 days; this biphasic
pattern is characterized by initial burst release followed
by a slow and continuous release rate as shown in the
figure. This pattern of release is still the same even after
laser irradiation at power intensity of 150 mW/cm2 for
11 min as in Fig. 5b which shows the initial fast release
of 5-ALA was probably due to 5-ALA, which was
adsorbed or close to the surface of the nanoparticles and
diffused out of the nanoparticles into the released med-
ium. The large surface-to-volume ratio of the nanoparti-
cles geometry can be the contributing factor for the initial
fast release pattern. The slow release of 5-ALA can be
attributed to the diffusion of 5-ALA entrapped in the core
of the nanoparticles into the aqueous media surrounding
the nanoparticles. The release pattern observed in our




At time of laser irradiation, all subgroups were monitored
for temperature which revealed an increase in temperature
of all subgroups compared with that before laser irradia-
tion. While temperature in the subgroups that were injected
with free 5-ALA and PLGA-encapsulated 5-ALA NPs
increased significantly compared with the control group
and the subgroup injected with blank PLGA NPs after laser
irradiation (Fig. 6). This increased temperature confirmed
by a necrosis occurs in the mice which was irradiated by
laser and had taken free 5-ALA than that is not irradiated
with laser where necrosis was found on histological
examination of sections from each tumor. The areas of










PDE % 66.8 %
DLE % 12.74 %
Fig. 5 Pattern of drug release of 5-ALA from PLGA NPs a without laser irradiation, b with laser beam for 11 min of power intensity 150 mW/
cm2 as a function of time
Fig. 6 Temperature change in
the subgroups before and after
irradiation with laser beam at
670 nm (150 mW/cm2) for
11 min
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necrosis in irradiated tumors were larger (higher rank) than
areas of necrosis of non-irradiated tumors (Egger et al.
1997).
Tumor growth and growth rate
All tumor volumes were normalized to that at the first day
of treatment. All the four studied subgroups that were not
irradiated with laser showed rapid tumor growth as shown
in Fig. 7a. Mice bearing Ehrlich ascites carcinoma injected
with free 5-ALA and irradiated with laser beam for 11 min
showed reduced tumor volume compared to mice injected
saline (control group) Fig. 7b. A severe decrease in tumor
volume were seen in the subgroup of mice bearing Ehrlich
ascites carcinoma, injected with PLGA-encapsulated
5-ALA NPs and irradiated with laser beam Fig. 7b. These
results are in accordance with the results obtained by Lee
et al. (2012) and Fadel et al. (2010). They formulated
nanoparticles from the biodegradable copolymer poly
(lactic-co glycolic acid) (PLGA) for targeting of zinc (II)
phthalocyanine (ZnPc) for PDT in Ehrlich ascites carci-
noma bearing mice. Tumor-bearing mice injected with
ZnPc NPs exhibited significantly smaller mean tumor
volume, increased tumor growth delay when compared
with the control group and the group injected with free
ZnPc during the time course of the experiment. Histopa-
thological examination of tumor from animals treated with
PLGA-ZnPc showed regression of tumor cells, in contrast
to those obtained from animals treated with free ZnPc
(Fadel et al. 2010).
Tumor growth inhibition
No significant difference in tumor volume was found
among subgroups before treatment. For all the studied
subgroups with no laser irradiation, the tumor grew rapidly
in mice of the control group, in which the mean tumor
volume after 21 days was 60.99 times greater than that at
the beginning as seen in Table 2.
For subgroups irradiated with laser beam, the tumor
grew rapidly in mice of the control group, in which the
mean tumor volume after 21 days was 39.72 times greater
than that at the beginning as shown in Table 3. In contrast,
tumor growth was less in volume in mice injected with free
5-ALA and PLGA-encapsulated 5-ALA NPs. The group










0 10 20 30





































0 10 20 30































Fig. 7 Tumor growth curves for the studied subgroups a without laser irradiation. b With laser irradiation at 670 nm (150 mW/cm2) for 11 min
Table 2 Tumor volume, tumor volume ratio (TVR) and inhibition









Before treatment 36.73 45.22 33.47 46.57
After 21 days of treatment 2,240.32 1,655.258 1,311.954 3,767.16
Tumor volume
ratio (TVR)
60.99 36.60 39.19 80.89
Inhibition ratio of tumor
after treatment (%)
26.9 42 -68
Table 3 Tumor volume, tumor volume ratio (TVR) and inhibition








Before treatment 37.58 39.75 44.21 45.74
After 21 days of treatment 1,492.92 1,082.7 530.76 302.3
Tumor volume ratio (TVR) 39.72 27.24 12 6.61
Inhibition ratio of tumor
after treatment (%)
28.33 66.6 82.4
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statistical significance difference in tumor volume com-
pared to that treated with blank PLGA NPs and also with
free 5-ALA as shown in Fig. 8.
Biochemical analysis
Figure 9 shows the mean serum levels of TNF-a in mice
bearing Ehrlich ascites carcinoma with no laser irradiation
were non-significantly changed (P = 0.115). While those
injected with free 5-ALA and PLGA-encapsulated 5-ALA
NPs and irradiated with laser showed significant reduction
of serum levels of TNF-a (P = 0.00) compared with those
injected with saline or blank PLGA NPs and irradiated with
laser. These results confirmed the presence of necrosis and/
or apoptosis which is confirmed by histopathological
examination.
Macroscopic analysis and histological studies of paraffin
section micrograph
Subgroups not treated with laser shows entirely viable
tumors formed of sheets of polymorphic hyperchromatic
malignant cells with bizarre giant forms and no evidence of
necrosis was identified as in Fig. 10a, but tumor begins to
be enhanced by exposing to laser beam 11 min 3 times per
week for 1 week as it shows an increase number of large
cells with visculated nuclei, reduction of multinucleate cell
and no infiltrating lymphocytes cells Fig. 10b. For sub-
groups injected with PLGA NPs and irradiated to laser, it
shows increase number of apoptotic cells characterized as
pycnotic nuclei with basophilic cytoplasm other with hal-
low of vacuolated cytoplasm (Fig. 10c). For subgroups
injected with 5-ALA only and irradiated with laser, it
shows increase number of apoptotic cells regenerative cells
characterized by vesicular nuclei and basophilic cytoplasm
cells normal blood vessel large necrotic areas as shown in
Fig. 10d. But for subgroup injected with PLGA-encapsu-
lated 5-ALA NPs and irradiated with laser exhibited an
improved in vivo PDT for the tumor site where it shows


















































































Fig. 8 Mean tumor volume for
all studied subgroups in the
absence and presence of laser
irradiation. a After 6 days of
treatment. b After 12 days.































Fig. 9 Biochemical analysis by TNF-a in blood serum for all
subgroups with and without laser irradiation
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and regenerative eosinophilic cytoplasm cells with viscu-
lated nuclei (Fig. 10e).
The administration of PLGA NPs resulted in a signifi-
cant growth inhibition of the KB tumor bearing nude mice
injected only once with PLGA NPs encapsulating chlorine
e6 (Ce6) (a commonly used photosensitizer) or free Ce6
where 24 h post-injection, tumor sites were locally illu-
minated at a light intensity of 5.2 mW/cm2 using a 670 nm
laser source for 40 min. The tumor volume in the nude
mice treated with PLGA NPs was approximately 1.5 or 3
times smaller than those treated with free Ce6 or PBS
(control). When compared to high-dose administration of
free Ce6 (2.5 mg/kg), low-dose administration of NP1 NPs
(equivalent Ce6 0.5 mg/kg body) were found to be more
efficient for tumor regression (Lee et al. 2012). Also our
results coincide with the results obtained by Fadel et al.
(2010).
Conclusion
As well as this study reports that entirely spherical shaped
PLGA nanospheres of (124 nm) mean size were efficiently
prepared by BOSD method rather than Spontaneous
Emulsification Diffusion (SESD) method, also the resultant
PLGA NPs allowed structural stability upon photosensi-
tizer loading expressed in the volumetric expansion indi-
cated by the increase in the mean particle size from empty
NPs to 5-ALA loaded ones. 5-ALA as a model of photo-
sensitizer was loaded to PLGA NPs with no deviation in
FTIR and TGA pattern in reference to PLGA polymer.
5-ALA showed bimodal release pattern from PLGA NPs
which is not affected by laser irradiation. This work
nominates PLGA-encapsulated 5-ALA NPs for in vivo
application of PDT studies, strongly supporting that laser-
irradiated PLGA-encapsulated 5-ALA NPs 5-ALA can
Fig. 10 Paraffin section micrograph for subgroups of Ehrlich ascites
carcinoma a untreated. b Irradiated with laser beam. c Injected with
free PLGA NPs and exposed to laser. d Injected free photosensitizer
(5-ALA) and exposed to laser. e Injected PLGA-encapsulated 5-ALA
NPs and exposed to laser
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effectively improve tumor PDT treatment options in terms
of tumor volume reduction, growth regression and histo-
pathology. We expect PLGA NPs to be tailor-made cus-
tomizable for the desired functionality advancing the
efficiency of anti-tumor management. So the feasibility of
drug-encapsulated nanoparticles systems has been demon-
strated and the advantages of such implanted systems are
well known and include mainly: (1) minimizing systemic
effects; (2) protecting the encapsulated drug from the
physiologic medium; (3) obtaining high and sustained
concentrations of the drug at the tumor site the particle
chosen in this study was nanospheres. Indeed, if the par-
ticles are small enough, then they can be injected either
through a needle into a discreet and functional area of the
tissue or directly into a tumor that cannot be restricted
because its location in turn will increase efficacy of PLGA-
encapsulated 5-ALA nanoparticles in mice bearing Ehrlich
ascites carcinoma.
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